Isoprenoids as mediators of the biological effects of statins

Journal of Clinical Investigation

Volumn 110, Issue 3, 2002, Pages 285-288

  Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; NITRIC OXIDE SYNTHASE; PRAVASTATIN; RAS PROTEIN; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; ENZYME INHIBITION; HUMAN; LIPOPHILICITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

EID: 0036322869     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216421     Document Type: Review

References (38)

1. Structural mechanism for statin inhibition of HMG-CoA reductase
2. HMG-CoA reductase inhibitors
3. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
4. New insights into the pharmacodynamic and pharmacokinetic properties of statins
5. Serum cholesterol in young men and subsequent cardiovascular disease
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
9. The MRC/BHF Heart Protection Study: Preliminary results
10. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
11. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.The MIRACL study: A randomized controlled trial
12. HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data
13. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study
14. Multiple risk factor intervention trial: Risk factor changes and mortality results
15. Regulation of the mevalonate pathway
16. Rho GTPases and signaling networks
17. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
18. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
19. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
20. Involvement of rho GTPases in the transcriptional inhibition of pre-proendothelin-1 gene expression by simvastatin in vascular endothelial cells
21. Effect of pravastatin on outcomes after cardiac transplantation
22. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study
23. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase
24. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
25. Molecular bases of the acute coronary syndromes
26. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
27. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
28. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells
29. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway
30. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease
31. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
32. Statins and the risk of dementia
33. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
34. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
35. Statins for the prevention of Alzheimer's disease
36. Cholesterol and Alzheimer's disease: Is there a link?
37. Low-density lipoprotein cholesterol and the risk of dementia with stroke
38. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events